

          1. Cannot obtain informed consent.

          2. Severe hepatic dysfunction (Child Pugh score >= C, or AST> 5 times the upper limit);
             Severe renal dysfunction (estimated glomerular filtration rate <= 30mL / min / 1.73 m2)
             or receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis.

          3. Unsatisfactory controlled hypertension (seated systolic blood pressure> 160mmHg, or
             diastolic blood pressure> 100mmHg); previous history of hypertension crisis or
             hypertensive encephalopathy.

          4. Poorly controlled heart diseases, such as NYHA class II and above cardiac
             insufficiency, unstable angina pectoris, myocardial infarction within 1 year before
             enrollment, supraventricular or ventricular arrhythmia need treatment or intervention.

          5. Hereditary bleeding tendency or coagulopathy; received full-dose anticoagulant or
             thrombolytic therapy within10 days before enrollment, or have taken non-steroidal
             anti-inflammatory drugs with platelet suppression within 10 days before enrollment
             (Except those who use small doses of aspirin <=325mg / day for preventive use).

          6. Thrombosis within 6 months before enrollment. And from those patients, screen who had
             arterial / venous thromboembolic events, such as, ischemic stroke, transient ischemic
             attack, deep venous thrombosis, pulmonary embolism, etc. within 1 year ahead of
             enrollment. Severe vascular disease (including aneurysms or arterial thrombosis
             requiring surgery) within 6 months before enrollment.

          7. Unhealed wounds, active gastric ulcers or fractures. Gastrointestinal perforation,
             gastrointestinal fistula, abdominal abscess, visceral fistula formation within 6
             months before enrollment. Major surgery (including preoperative Chest biopsy) or major
             trauma (such as a fracture) within 28 days before enrollment. May have surgery during
             the trial.

          8. Severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous
             system bleeding, and nosebleeds within 1 month before enrollment.

          9. Malignant tumors within 5 years before enrollment.

         10. Allergic to bevacizumab or its components.

         11. Untreated active hepatitis or HIV-positive patients.

         12. Pregnant and lactating women and those planning to get pregnant.

         13. Participated in other clinical trials, not considered suitable for this study by the
             researchers.
      